Recent Research from the ODPRN

COVID-19 Ontario Prescription Drug Utilization Tool

To help characterize the impact of COVID-19 on drug prescribing, this newly released tool provides public access to data on drug utilization in Ontario during the COVID-19 pandemic

Geographic variation in the provision of naloxone by pharmacies in Ontario

This study investigates regional variation in the distribution of naloxone through the ONPP and identifies individual- and public health unit-level determinants of variation.

Spending on hepatitis C antivirals in the United States and Canada, 2014 to 2018

This case-study explores differences in drug spending between Canada and the US to compare drug expenditures on hepatitis C virus medications.

Characteristics of high drug-cost beneficiaries across Canada: A cross-sectional pan-Canadian analysis

This study describes the characteristics of high drug-cost beneficiaries (the top 5% of public drug program beneficiaries based on annual costs) in 9 provinces across Canada, to inform current planning around national drug strategies.

Oxycodone, hydromorphone, and the risk of suicide: A retrospective population-based case-control study

This study explores whether oxycodone and hydromorphone are differentially associated with suicide.

Current and prospective utilization of innovator biologics and biosimilars in Ontario

This report describes the current and prospective utilization patterns and expenditures of innovator biologics and biosimilars through the public drug program in Ontario, Canada.


Additional Resources

Please note that this report is NOT COMPLETE and is still in progress. Click below if you would like to continue.